Pharmaceutical News

RSS

Pfizer's PD0325901 experimental drug blocks untreatable NF1 tumors

Researchers conducting a preclinical study in mice successfully used targeted molecular therapy to block mostly untreatable nerve tumors that develop in people with the genetic disorder Neurofibromatosis 1 (NF1).

11 Dec 2012

Janssen announces U.S. prescribing information update for EDURANT tablets

Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a prescribing information update for EDURANT (rilpivirine) tablets to include 96-week pooled data from the Phase 3 ECHO and THRIVE studies, which evaluated the efficacy and safety of EDURANT for the treatment of human immunodeficiency virus type 1 (HIV-1) in antiretroviral treatment-naive adults.

11 Dec 2012

Vaccines serve as 'engine for economic growth'

Vaccines "save lives by protecting people against disease," but they "also are an engine for economic growth -- far beyond their health benefits," GAVI Alliance CEO Seth Berkley writes in a CNN opinion piece.

11 Dec 2012

Naltrexone may help avoid weight gain among women smokers

A medication being tested to help smokers kick the habit also may help avoid the weight gain that is common after quitting but only in women, according to a study published in the December issue of Biological Psychiatry. This is the first medication shown to reduce weight gain for up to one year in women smokers who quit.

11 Dec 2012

SCOTUS agrees to hear 'pay-for-delay' drug case

The Supreme Court will hear arguments on the legality of drug companies paying their generic-making counterparts to keep generic drugs -- in this case, a testosterone gel -- off the market.

11 Dec 2012

Weill Cornell research team develops new experimental drug therapy to target DLBCL

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and the seventh most frequently diagnosed cancer. The most chemotherapy resistant form of DLBCL, called activated B-cell - DLBCL (ABC-DLBCL), remains a major therapeutic challenge.

11 Dec 2012

Governments, donors should follow PMI model of testing drugs for quality

"[W]e are losing the global fight against bad medicines," and though "[s]ome progress is being made," the "problem is that ... crackdowns tend to focus on counterfeit drugs" while a "much bigger public health problem ... is substandard drugs that are the result of shoddy manufacturing and handling -- or perhaps worse, deliberate corner-cutting," Roger Bate, a resident scholar at the American Enterprise Institute, writes in an opinion piece in The Hill's "Congress Blog."

11 Dec 2012

Almirall, Forest Laboratories' Tudorza Pressair now available in the U.S. pharmacies

Forest Laboratories, Inc. and Almirall, S.A. announced today that Tudorza Pressair (aclidinium bromide inhalation powder) 400mcg is now available in pharmacies throughout the United States.

11 Dec 2012

Acetylon announces results from selective HDAC 1/2 inhibitor preclinical study on SCD and bT

Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced results from a preclinical study of a selective histone deacetylase (HDAC) 1/2 inhibitor for the treatment of sickle cell disease (SCD) and beta-thalassemia (bT) at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place in Atlanta, Georgia.

11 Dec 2012

Oxytocin administration to fathers increases parental engagement with their infants

A large body of research has focused on the ability of oxytocin to facilitate social bonding in both marital and parenting relationships in human females. A new laboratory study, led by Dr. Ruth Feldman from Bar-Ilan University in Israel and published in the current issue of Biological Psychiatry, has found that oxytocin administration to fathers increases their parental engagement, with parallel effects observed in their infants.

11 Dec 2012

Isis, Biogen Idec partner to discover and develop antisense drugs against neuromuscular disorders

Biogen Idec and Isis Pharmaceuticals, Inc. today announced that they have entered into a global collaboration agreement under which the companies will discover and develop antisense drugs against three undisclosed targets to treat neurological or neuromuscular disorders.

11 Dec 2012

FDA expands approved use of Janssen Biotech’s Zytiga to treat men with mCRPC

The U.S. Food and Drug Administration today expanded the approved use of Zytiga (abiraterone acetate) to treat men with late-stage (metastatic) castration-resistant prostate cancer prior to receiving chemotherapy.

10 Dec 2012

Janssen receives FDA approval for ZYTIGA to treat metastatic castration-resistant prostate cancer

Janssen announced today that the U.S. Food and Drug Administration (FDA) has approved a broader indication for the oral, once-daily medication ZYTIGA (abiraterone acetate).

10 Dec 2012

New study could help develop anti-inflammatory drugs with fewer side effects

10 Dec 2012

Despite effective anti-viral drugs, majority of HCV patients remain untreated

Just 20 percent of people infected with the hepatitis C virus (HCV) begin the recommended treatment regimen and less than 5 percent go on to successfully overcome the virus, according to a new review in General Hospital Psychiatry.

10 Dec 2012

Bicycle Therapeutics secures £3.75 million equity financing for drug discovery

Bicycle Therapeutics, a next generation biotherapeutics company co-founded by Sir Gregory Winter and Professor Christian Heinis, today announced that it had secured a tranched equity financing of £3.75 million to invest in selection of drug candidates using its bicyclic peptide technology platform.

10 Dec 2012

DOW Chemical to attend the 4th World Drug Delivery & Formulation Summit

The pharmaceutical industry is experiencing a massive paradigm shift as the era of the highly profitable blockbusters comes to a close. In an attempt to remain competitive, companies are under more pressure than ever to push novel compounds through the development pipeline and so it has been largely left to those in formulation and delivery to optimise their product portfolio using winning business strategies and leading technologies.

10 Dec 2012

Perceptive Informatics launches Customer Care office in Shanghai to serve biopharmaceutical researchers

Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), today announced that it has opened a Customer Care office in Shanghai to service biopharmaceutical researchers in China and Taiwan who are using Perceptive's technology solutions.

From Parexel 10 Dec 2012

Vorinostat reduces risk of graft-vs.-host disease from bone marrow transplant treatments

A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments, according to a study from researchers at the University of Michigan Comprehensive Cancer Center.

10 Dec 2012

Nuron Biotech announces acquisition of Meningitec from Pfizer

Nuron Biotech Inc., a specialty biologics and vaccines company, today announced it has acquired from Pfizer Inc. Meningitec, which is a vaccine for the prevention of invasive disease caused by Neisseria meningitidis serogroup C.

10 Dec 2012

Pharmaceutical News

Pfizer's PD0325901 experimental drug blocks untreatable NF1 tumors

Janssen announces U.S. prescribing information update for EDURANT tablets

Vaccines serve as 'engine for economic growth'

Naltrexone may help avoid weight gain among women smokers

SCOTUS agrees to hear 'pay-for-delay' drug case

Weill Cornell research team develops new experimental drug therapy to target DLBCL

Governments, donors should follow PMI model of testing drugs for quality

Almirall, Forest Laboratories' Tudorza Pressair now available in the U.S. pharmacies

Acetylon announces results from selective HDAC 1/2 inhibitor preclinical study on SCD and bT

Oxytocin administration to fathers increases parental engagement with their infants

Isis, Biogen Idec partner to discover and develop antisense drugs against neuromuscular disorders

FDA expands approved use of Janssen Biotech’s Zytiga to treat men with mCRPC

Janssen receives FDA approval for ZYTIGA to treat metastatic castration-resistant prostate cancer

New study could help develop anti-inflammatory drugs with fewer side effects

Despite effective anti-viral drugs, majority of HCV patients remain untreated

Bicycle Therapeutics secures £3.75 million equity financing for drug discovery

DOW Chemical to attend the 4th World Drug Delivery & Formulation Summit

Perceptive Informatics launches Customer Care office in Shanghai to serve biopharmaceutical researchers

Vorinostat reduces risk of graft-vs.-host disease from bone marrow transplant treatments

Nuron Biotech announces acquisition of Meningitec from Pfizer

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News